• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Switching from one infliximab biosimilar (CT-P13) to another infliximab biosimilar (SB2) in patients with chronic plaque psoriasis.

作者信息

Gisondi P, Virga C, Piaserico S, Meneguzzo A, Odorici G, Conti A, Girolomoni G

机构信息

Department of Medicine, Section of Dermatology and Venereology, University of Verona, Verona, Italy.

Department of Medicine, Section of Dermatology and Venereology, University of Padua, Padua, Italy.

出版信息

Br J Dermatol. 2020 Aug;183(2):397-398. doi: 10.1111/bjd.19013. Epub 2020 Apr 13.

DOI:10.1111/bjd.19013
PMID:32133618
Abstract
摘要

相似文献

1
Switching from one infliximab biosimilar (CT-P13) to another infliximab biosimilar (SB2) in patients with chronic plaque psoriasis.在慢性斑块状银屑病患者中从一种英夫利昔单抗生物类似药（CT-P13）转换为另一种英夫利昔单抗生物类似药（SB2）。
Br J Dermatol. 2020 Aug;183(2):397-398. doi: 10.1111/bjd.19013. Epub 2020 Apr 13.
2
Comparative effectiveness of the biosimilar CT-P13.生物类似药CT-P13的比较疗效
J Comp Eff Res. 2017 Nov;6(8):693-712. doi: 10.2217/cer-2017-0033. Epub 2017 Sep 12.
3
Infliximab biosimilar CT-P13 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars registry.英夫利昔单抗生物类似药CT-P13治疗慢性斑块状银屑病：来自Psobiosimilars注册研究的数据
Br J Dermatol. 2017 Dec;177(6):e325-e326. doi: 10.1111/bjd.15659. Epub 2017 Nov 22.
4
Clinical experience with infliximab biosimilar in psoriasis.英夫利昔单抗生物类似药治疗银屑病的临床经验。
Br J Dermatol. 2017 Dec;177(6):e347-e348. doi: 10.1111/bjd.15755. Epub 2017 Nov 15.
5
Similar But Not Identical: Plaque Psoriasis Exacerbation in a Patient With Crohn's Disease After Switching From CT-P13 to SB2 Infliximab Biosimilar.相似但不相同：克罗恩病患者从CT-P13换用SB2英夫利昔单抗生物类似药后出现斑块状银屑病加重
Inflamm Bowel Dis. 2020 Jul 17;26(8):e83-e84. doi: 10.1093/ibd/izaa128.
6
Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease.炎症性肠病患者从英夫利昔单抗原药转换为英夫利昔单抗生物类似药（CT-P13）后疗效和安全性丧失。
World J Gastroenterol. 2018 Dec 14;24(46):5288-5296. doi: 10.3748/wjg.v24.i46.5288.
7
Switching from originator to biosimilar infliximab - real world data of a prospective 18 months follow-up of a single-centre IBD population.从英夫利昔单抗原研药转换为生物类似药——单中心炎症性肠病患者前瞻性18个月随访的真实世界数据
Scand J Gastroenterol. 2018 Jun;53(6):692-699. doi: 10.1080/00365521.2018.1463391. Epub 2018 May 31.
8
Outcomes after double switching from originator Infliximab to biosimilar CT-P13 and biosimilar SB2 in patients with inflammatory bowel disease: a 12-month prospective cohort study.炎症性肠病患者从原研英夫利昔单抗转换至生物类似药 CT-P13 和 SB2 后的结局：一项 12 个月前瞻性队列研究。
Aliment Pharmacol Ther. 2021 Apr;53(8):887-899. doi: 10.1111/apt.16312. Epub 2021 Mar 1.
9
Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial.生物类似药英夫利昔单抗（CT-P13）在转换为原研药英夫利昔单抗后的长期疗效和安全性：NOR-SWITCH 试验的开放标签扩展。
J Intern Med. 2019 Jun;285(6):653-669. doi: 10.1111/joim.12880. Epub 2019 Apr 12.
10
Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): a large single-centre experience.英夫利昔单抗生物类似药CT-P13用于炎症性肠病（IBD）起始治疗或换药治疗的疗效及耐受性：一项大型单中心研究经验
Scand J Gastroenterol. 2018 Jun;53(6):700-707. doi: 10.1080/00365521.2018.1464203. Epub 2018 Apr 24.

引用本文的文献

1
Long-term Safety Monitoring and Efficacy Status of Infliximab and its Biosimilars in Psoriasis Management.英夫利昔单抗及其生物类似药治疗银屑病的长期安全性监测与疗效状况
Curr Drug Saf. 2025;20(3):271-286. doi: 10.2174/0115748863320685240830092746.
2
Additional Data in Expanded Patient Populations and New Indications Support the Practice of Biosimilar-to-Biosimilar Switching.扩大患者群体和新适应症中的更多数据支持生物类似药之间换药的做法。
BioDrugs. 2024 May;38(3):331-339. doi: 10.1007/s40259-024-00655-4. Epub 2024 Mar 23.
3
Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease: clinical outcomes in real-world patients from the DANBIO registry.
英夫利昔单抗生物类似药-生物类似药转换治疗炎症性风湿病患者：DANBIO 注册研究中真实世界患者的临床结局。
RMD Open. 2022 Nov;8(2). doi: 10.1136/rmdopen-2022-002560.
4
Switching Among Biosimilars: A Review of Clinical Evidence.生物类似药之间的转换：临床证据综述
Front Pharmacol. 2022 Aug 24;13:917814. doi: 10.3389/fphar.2022.917814. eCollection 2022.
5
Effectiveness of infliximab biosimilars in the treatment of moderate to severe chronic plaque psoriasis: experience of real-world data from the register of the program "Treatment of moderate and severe forms of plaque psoriasis (B.47)" of the National Health Fund in Poland.英夫利昔单抗生物类似药治疗中度至重度慢性斑块状银屑病的有效性：来自波兰国家卫生基金“中度和重度斑块状银屑病（B.47）治疗”项目登记册的真实世界数据经验
Postepy Dermatol Alergol. 2022 Aug;39(4):723-728. doi: 10.5114/ada.2021.108442. Epub 2021 Aug 16.
6
Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies.从一种生物类似药切换至同一种参照生物制品的另一种生物类似药：研究的系统评价。
BioDrugs. 2022 Sep;36(5):625-637. doi: 10.1007/s40259-022-00546-6. Epub 2022 Jul 26.
7
Effectiveness and Safety of Adalimumab Biosimilar SB5 in Inflammatory Bowel Disease: Outcomes in Originator to SB5 Switch, Double Biosimilar Switch and Bio-Naïve SB5 Observational Cohorts.阿达木单抗生物类似药 SB5 在炎症性肠病中的疗效和安全性：原研药至 SB5 转换、双生物类似药转换和生物初次使用 SB5 观察队列的结局。
J Crohns Colitis. 2021 Dec 18;15(12):2011-2021. doi: 10.1093/ecco-jcc/jjab100.
8
Long-term effectiveness, safety and immunogenicity of the biosimilar SB2 in inflammatory bowel disease patients after switching from originator infliximab.从原研英夫利昔单抗转换后，生物类似药SB2在炎症性肠病患者中的长期有效性、安全性和免疫原性。
Therap Adv Gastroenterol. 2021 Jan 14;14:1756284820982802. doi: 10.1177/1756284820982802. eCollection 2021.